Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Labrador who wrote (1390)	11/12/1998 5:46:00 PM
From: Rocketman	Read Replies (1) \| Respond to of 2135

Go onto Yahoo pull up an ENMD quote and try and find the WSJ article. It isn't there and the other new services didn't pick it up either until way late in the day. <<<<<<<<< Reuters at 2:53PM EST ENTREMED INC (Nasdaq:ENMD - news) OFF 6-15/16 AT 25-3/4 Shares fell after the Wall Street Journal said scientists working independently have not been able to verify the findings of Jonah Folkman, who developed the compound said to shrink tumors by cutting off the flow of blood. CEO John Holaday said the development of anti-cancer drug endostatin is proceeding as planned. >>>>>>>> Sure WSJ and CNBC have it. And hard core traders and investors will have picked up on it, but not the mom and pop investors who have made bets that ENMD WILL CURE cancer soon. Bet you won't see anything in IBD until tomorrow, how about this mornings newspapers, not there either. At Discover online brokerage there was no ENMD news when I checked earlier (but they SUCK so this isn't a very good example). The WSJ article hasn't gotten any where near the play that it will, YET. I'm curious whether the national and local newscasts pick up the story tonight.